Recent developments highlight Dermata's strategic shift, clinical progress, financial activities, and litigation status.

• Dermata announced a private placement valued at up to $12.4 million in December 2025 to support its operations and product launches [N1].
• The company plans to launch its first OTC acne kit in mid-2026 as part of its new direct-to-consumer skincare strategy [N2].
• Dermata reported a narrower loss in Q2 2025, indicating some improvement in financial performance [N3].
• Enrollment in the DMT310 Phase 3 STAR-1 trial was completed as of December 2024, supporting clinical development efforts [N4].
• Dermata is involved in ongoing litigation with Villani, Inc. regarding its Spongilla-based products, with recent court rulings denying preliminary injunctions but continuing legal proceedings [S2].

Dermata leverages a unique natural ingredient with scientific backing to address large consumer skincare markets, including acne and skin renewal. The strategic shift to OTC and cosmetic products aligns with changing consumer preferences for accessible, effective, and natural skincare solutions. The company's planned product launches and professional certification program could facilitate market penetration and brand recognition. Exclusive supply and intellectual property protections support competitive differentiation. Successful commercialization and expansion of the product portfolio could enhance Dermata's market presence.

Dermata faces risks from ongoing litigation with Villani, Inc. that could restrict or delay commercialization of its Spongilla-based products. The company operates in a highly competitive skincare market with many established players and evolving consumer trends. Regulatory and Nasdaq listing compliance challenges pose additional risks. The strategic shift from prescription drugs to OTC and cosmetic products involves execution risks, including market acceptance and scaling sales channels. Financial losses and limited liquidity may constrain operational flexibility.

Dermata's moat is based on its proprietary Bioneedle technology derived from Spongilla lacustris, a unique freshwater sponge ingredient with distinctive organic and mechanical properties. The company maintains exclusive supply agreements and is strengthening its intellectual property portfolio. Its clinical knowledge and strategic shift to OTC and cosmetic skincare products backed by science differentiate it in a competitive skincare market. The planned certification program for skincare professionals and potential global partnerships may further enhance its market position. However, the moat is subject to risks from ongoing litigation and regulatory challenges.

• Litigation Risk: Dermata is involved in ongoing litigation and arbitration with Villani, Inc. related to its Spongilla-based products, which could result in restrictions, delays, or increased costs affecting commercialization and operations.
• Nasdaq Listing Compliance: The company faces risks of delisting due to market value of listed securities falling below Nasdaq's $5 million threshold, which could impact stock liquidity, financing ability, and investor confidence.
• Execution Risk: The strategic shift to OTC and cosmetic skincare products requires successful product launches, brand building, and market acceptance, with risks related to competition and consumer preferences.
• Financial Risk: Dermata reported net losses and has limited cash resources, which may affect its ability to fund operations, product development, and commercialization efforts.

• Dermata Therapeutics, Inc. is a scientific leader in skincare focused on developing and commercializing products addressing common and underserved skin conditions, initially focusing on prescription products subject to FDA approval, with a lead asset XYNGARI (DMT310) for moderate-to-severe acne.
• In March 2025, Dermata announced statistically significant results from its Phase 3 STAR-1 clinical trial of XYNGARI for moderate-to-severe acne, meeting all three co-primary endpoints at weeks 4, 8, and 12 compared to placebo.
• In September 2025, Dermata strategically shifted from prescription acne products to developing and distributing direct-to-consumer (DTC) and business-to-business (B2B) skincare products, aiming for faster commercialization and reduced regulatory burden.
• The company plans to leverage its clinical knowledge and its hero ingredient, Spongilla lacustris, a freshwater sponge-derived powder called Bioneedle, to develop cosmetic and OTC skincare treatments.
• Dermata intends to launch its first cosmetic product in mid-2026, followed shortly by its first OTC acne product, both incorporating Bioneedle technology.
• The Bioneedle ingredient is processed to optimize mechanical and organic properties, eliminating harmful bacteria, and is used in a weekly skin renewal foundational treatment and a daily salicylic acid wipe clearing treatment for acne.
• Dermata plans to sell products through its website as monthly subscriptions or one-month kits and also to medical professionals for in-office treatments, targeting broad consumer segments.
• The company aims to expand its OTC product portfolio to treat various skin diseases including psoriasis and seborrheic dermatitis, using Bioneedle technology combined with OTC monograph active ingredients.
• Dermata is building a certification program for skincare professionals to deliver in-office Tome therapy sessions, offering exclusive access to products and events.
• The company is exploring partnerships and distribution agreements globally to commercialize its products and plans to strengthen its intellectual property portfolio and maintain exclusive raw material supply.
• Dermata completed enrollment in the DMT310 Phase 3 STAR-1 trial as of December 2024.
• Dermata announced a private placement valued at up to $12.4 million in December 2025.
• The company reported a narrower loss in Q2 2025.
• Dermata's common stock is listed on Nasdaq Capital Market but faces risks related to continued listing requirements, including market value thresholds.
• As of June 30, 2026, Dermata had cash and cash equivalents of approximately $4.41 million and current assets of about $5.16 million, with a current ratio of 3.4 and a cash ratio of 2.91, indicating liquidity.
• Net income for the quarter ended June 30, 2026, was a loss of approximately $2.97 million, with basic and diluted EPS of -$0.74 per share.
• Dermata is involved in litigation with Villani, Inc. regarding Spongilla-based products, including claims of false advertising and breach of contract; the litigation is ongoing with no current injunctive restrictions but potential risks to commercialization.
• The company’s strategic repositioning focuses on leveraging natural ingredients with scientific backing to meet changing consumer preferences favoring OTC and cosmetic skincare products that simplify routines and offer efficacy and safety without prescriptions.